News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_86f7f6300f1dd303d3_CLL_Leukemia_3.jpg)
CAR T-cell therapy eyed for CLL patients with residual disease
- Author:
- Mary Jo Dales
Key clinical point: CAR T-cell therapy may be an option for chronic lymphocytic leukemia patients with residual disease after upfront therapy....
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_1379208e54880cef56_red_blood_cells.jpg)
The liver drives RBC elimination, iron recycling
- Author:
- Mary Jo Dales
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_107255218f99193904_CLL_leukemia.jpg)
Three-drug regimen boosts progression-free survival in patients with relapsed CLL and adverse prognostic features
- Author:
- Mary Jo Dales
Key clinical point: Progression-free survival was improved for poor prognosis patients with relapsed chronic lymphocytic leukemia when idelalisib...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_ed0056b379fe3763f0_CML_leukemia.jpg)
Treatment-free remissions achieved in patients with chronic myeloid leukemia
- Author:
- Mary Jo Dales
Key clinical point: Treatment-free remission attempts are safe and are achievable in most patients with chronic myeloid leukemia in chronic phase...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_9c229ab192d66399be_MultipleMyeloma.jpg)
Smoldering multiple myeloma affects 1 in 7 patients
- Author:
- Mary Jo Dales
Key clinical point: The prevalence of smoldering multiple myeloma varied among various socio- and geodemographic subgroups, but overall survival...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_89c216e9a03d0be75f_TTP.jpg)
Mechanism proposed for microvascular thrombosis in thrombotic thrombocytopenic purpura
- Author:
- Mary Jo Dales
Key clinical point: In patients with acquired autoimmune thrombotic thrombocytopenic purpura, elevated plasma levels of human neutrophil proteins...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_302b015d8753ef070d_blood_circulation.jpg)
Dematin key to erythrocyte membrane stability in mice
- Author:
- Mary Jo Dales
Key clinical point: Dematin is newly recognized as a protein crucial to the integrity of red blood cell membranes. Major finding: Dematin’s...
News
Adding obinutuzumab to bendamustine boosts progression-free survival in rituximab-refractory indolent non-Hodgkin lymphoma
- Author:
- Mary Jo Dales
Key clinical point: Obinutuzumab is an option when patients with indolent non-Hodgkin lymphoma relapse or don’t achieve adequate disease control...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_91b2f39eed96e6bdac_Byrd_John_Ohio.jpg)
Acalabrutinib shows efficacy as monotherapy in untreated CLL
- Author:
- Mary Jo Dales
Key clinical point: Acalabrutinib, which has shown efficacy in relapsed CLL, has now shown efficacy as a monotherapy for patients with previously...
News
Ibrutinib at below standard dose may achieve good survival in CLL
- Author:
- Mary Jo Dales
Key clinical point: Ibrutinib given at doses lower than the standard dose of 420 mg/day may achieve comparable overall survival and progression-...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_8cd4c302fbedb2ee53_118845_Phillips_Adrienne_NY.jpg)
Mogamulizumab achieves objective responses in relapsed/refractory adult T-cell leukemia-lymphoma
- Author:
- Mary Jo Dales
Key clinical point: The anti-CCR4 monoclonal antibody mogamulizumab was superior to other investigator-selected therapies for the treatment of...
News
Alemtuzumab plus CHOP didn’t boost survival in elderly patients with peripheral T-cell lymphomas
- Author:
- Mary Jo Dales
Key clinical point: Adding the monoclonal anti-CD52 antibody alemtuzumab to CHOP (A-CHOP) increased response rates in elderly patients with...
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Antibodies cut factor VIII half-life in patients with hemophilia A
- Author:
- Mary Jo Dales
Key clinical point: Non-neutralizing, factor VIII–specific IgG antibodies can contribute significantly to reductions in factor VIII half-life in...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_7adb29ad9068c696c9_118788 Dartigeas_Caroline.jpg)
Maintenance rituximab extends progression-free but not overall survival in CLL
- Author:
- Mary Jo Dales
Key clinical point: Progression-free survival, but not overall survival, was improved after 2 years of maintenance immunotherapy with rituximab....
News
Brentuximab vedotin boosted PET-negative rate in Hodgkin
- Author:
- Mary Jo Dales
Key clinical point: Brentuximab vedotin appears to eradicate residual disease after induction chemotherapy in a small study of patients with...